Wednesday, November 11, 2026
ExploreSearch
Via News

Autonomous Robotics

3 articles

Autonomous Robotics Breaks Into Consumer Markets as LiDAR and Neuromorphic AI Mature Through 2026

Autonomous Robotics Breaks Into Consumer Markets as LiDAR and Neuromorphic AI Mature Through 2026

Commercial robotics deployments are accelerating across manufacturing, consumer services, and autonomous vehicles between Q1-Q4 2026, powered by advances in LiDAR navigation, SLAM mapping, and neuromorphic vision systems. Artificial Intelligence Technology Solutions' RADSight 2.0 cuts power consumption by over 50% while companies from Swisslog to robotaxi operators launch products spanning industrial automation to home services. The shift marks autonomous systems moving from controlled environme

ViaNews Editorial Team (AI department)•
Autonomous Robotics Push Toward 2026-2028 Commercial Deployment Across Manufacturing, Mobility, and Medical Sectors

Autonomous Robotics Push Toward 2026-2028 Commercial Deployment Across Manufacturing, Mobility, and Medical Sectors

Multiple autonomous robotics platforms are targeting commercial launch between 2026-2028, spanning industrial automation from ABB, delivery vehicles from Nuro and Serve Robotics, and medical exoskeletons from Lifeward. The Nokia-NVIDIA AI-RAN infrastructure partnership and 2027 DoD sourcing rules provide the network backbone and regulatory framework enabling mass deployment.

ViaNews Editorial Team (AI department)•
Robotaxi Production Targets 2026 as Warehouse Bots Hit 98% Handling Rates

Robotaxi Production Targets 2026 as Warehouse Bots Hit 98% Handling Rates

Physical AI systems are moving from labs to commercial deployment across robotics sectors. Warehouse automation now handles 98% of shoeboxes, robotaxi production is scheduled for late 2026, and medical exoskeletons are clearing regulatory hurdles. Chinese robotics firms are accelerating global adoption by cutting deployment timelines from years to months.

ViaNews Editorial Team (AI department)•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,564 source documents archived
Query this data → isubstrate.com